Sanjiv Sam Gambhir, MD, PhD
Comparison of I-124 PET/CT, F-18 FDG PET/CT & I-123 whole body scintigraphy for recurrent thyroid CA
Contact Information
Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305Brief
The management of thyroid cancer patients with suspicion of recurrent disease based on rising/detectable levels of thyroglobulin (Tg) involves imaging with iodine-123 whole body scintigraphy (I-123 WBS) and F-18 FDG PET/CT. However, the disease is not always detected. The use of another iodine isotope (I-124) with positron emitting characteristics for PET/CT may allow better identification of recurrent disease, thus allowing for more patients to be treated with I-131 as a curative attempt.
Recruiting Status:
No longer recruitingStanford Recruiting Status:
No longer recruitingCondition(s):
Intervention(s):
- Procedure: Iodine-124 PET/CT
Phase:
N/AEligibility
Ages Eligible for Study:
18 years to Any AgeGenders Eligible for Study:
Male and FemaleHealth of Volunteers:
People with the conditions listed in this trial can participate as controls.Key Inclusion Criteria:
- Patient at Nuclear Medicine clinic at Stanford University Medical Center
- Treated thyroid cancer.
- Detectable levels of Tg.
- Referred for I-123 WBS and F-18 FDG PET/CT for detection of recurrent thyroid cancer.
- Able to have a I-124 PET/CT the day after I-123 WBS and F-18 FDG PET/CT
- Patients older than 18-year-old.
- Patients with history of treated thyroid cancer and suspected recurrent thyroid cancer based on detectable levels of Tg.
- Patients must have I-123 WBS and F-18 FDG PET/CT performed prior to the I-124 PET/CT.
- Patients must understand and voluntarily sign an Informed Consent form after the contents have been fully explained to them.
Key Exclusion Criteria:
- Patients who are not eligible for I-123 WBS and F-18 FDG PET/CT.
- Patients who cannot complete I-123 WBS and F-18 FDG PET/CT.
- Pregnant women.
- Healthy volunteers.
- Patients participating in other research studies.
Additional Study Details
Official Title:
Comparison of I-124 PET/CT, F-18 FDG PET/CT and I-123 whole body scintigraphy for recurrent thyroid cancer detectionAnticipated start date:
5/2/2007Lead Sponsor:
Stanford UniversityInvestigator(s):
Study Type:
InterventionalPurpose:
DiagnosticAllocation:
Non-randomizedMasking:
OpenControl:
noneAssignment:
Single GroupEndpoints:
UnspecifiedPrimary Outcomes:
- Testing the hypothesis that I-124 PET/CT will detect more lesions than I-123 WBS and F-18 FDG PET/CT.
Secondary Outcomes:
- Evaluating I-124 as a PET/CT radiotracer
- Evaluating the imaging protocol that combines I-124 PET/CT and F-18 FDG PET/CT.
Total Number to be Enrolled:
100Total Number to be Enrolled at Stanford:
100More Information
Secondary ID(s):
- 97454
- END0003
- NCT00373711
Locations & Contacts
Stanford Locations & Contacts:
Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305Non-Stanford Locations:
The Stanford website does not have any locations outside of Stanford listed for this trial. You may want to check clinicaltrials.gov for posible additional locations.
This listing was last updated:
5/21/2009PLEASE NOTE:
Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician. If you do not have a primary care physician please feel free to call the SHC Physician Referral Service at (800) 756-9000 or send an email.
Help
Trial Administration